your badges 52W Range $69–$161 61% of range Analyst Rating BUY 22 analysts Price Target $229 +83% upside P/E -33.7 ROE -110.1% Net Profit Margin -1610.6%

PVLA Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

03
Price $125.10
Market Cap (MRQ) $1.80B
P/E -33.7
EPS $-3.71
Revenue $43M
ROE -110.1%
52W Range $69–$161

PVLA Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

04
range
bars

Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.

Stock splits 1
Ex-date Split Type
April 23, 2024 1-for-80 Reverse

10-Year Performance Revenue, net income, margins and EPS trends

06
Revenue$43M
2017-12-31 → 2023-12-31
EPS$-3.71
2020-12-31 → 2025-12-31
Free Cash Flow·
2017-12-31 → 2022-12-31
Net margin-1610.6%
2017-12-31 → 2025-12-31
Valuation & Ratios 07–12

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric 5Y trend PVLA 5Y avg Peer Median Verdict
P/E -33.75Y avg ≈-113.6 ≈-113.6 · ·
P/S 79.15Y avg ≈104.1 ≈104.1 11.4 Overvalued
P/B (MRQ) 8.35Y avg ≈90.1 ≈90.1 3.4 Overvalued
Price / Cash Flow -61.95Y avg ≈-55.8 ≈-55.8 · ·
Price / Tangible Book 55.35Y avg ≈159.6 ≈159.6 · ·

Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.

value · ≈ 5Y avg · industry median · verdict relative to median

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

14
Avg Surprise -53.9%
Next Report Nov 17, 2026
PeriodReportEPS ActualEPS EstSurprise
June 30, 2026 Aug 13, 2026 $-1.52 $-1.18 -28.5%
March 31, 2026 May 14, 2026 $-1.20 $-0.95 -26.2%
Dec. 31, 2025 $-1.07 $-0.93 -15.2%
Sept. 30, 2025 $-1.03 $-0.86 -20.5%
June 30, 2025 $-0.86 $-0.76 -13.8%
March 31, 2025 $-0.74 $-1.24 40.1%
Dec. 31, 2024 $-2.72 $-0.66 -313.4%

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

15
Income Statement 15
Metric Trend 202520242023202220212020201920182017201620152014
Revenue ··$43M$26M$31M$29M$46M$29M$25M$6M$3M$5M
R&D Expense $23M$8M$9M$53M$67M$47M$55M$41M$22M$20M$8M$6M
SG&A Expense $16M$6M$3M$16M$17M$17M$18M$18M$18M$9M$8M$7M
Operating Expenses $39M$14M$12M$69M$83M$63M$73M$60M$40M$29M$17M$13M
Operating Income $-39M$-14M$-12M$-43M$-52M$-34M$-27M$-31M$-15M$-23M$-14M$-7M
Interest Expense ···········$3M
Other Non-op $727.0K$-131.0K$712.0K$1M$2M$-4M$-26.0K$2M$-2M$120.0K$10.9K$3.0K
Pretax Income $-42M$-17M$19M$-33M$-46M$-37M$-25M$-27M$-17M$-23M$-14M$-10M
Income Tax $0$0$0$0$0$164.0K$0$-312.0K$1M$162.0K$203.9K$-18
Net Income $-42M$-17M$19M$-33M$-46M$-37M$-25M$-27M$-18M$-23M$-14M$-10M
EPS (Basic) $-3.71$-7.83$2.19$-0.45$-0.71$-0.68······
EPS (Diluted) $-3.71$-7.83$2.17·$-0.71$-0.68······
Shares (Basic) 11,251,2502,225,9341,770,16774,172,00064,547,00054,481,000······
Shares (Diluted) 11,251,2502,225,9341,793,980·64,547,00054,481,000······
EBITDA $-39M$-14M·$-41M·$-34M$-27M$-31M$-15M···
Balance Sheet 24
Metric Trend 202520242023202220212020201920182017201620152014
Cash & Equivalents $58M$84M$7M$39M$118M$70M$62M$75M$38M$29M$29M$18M
Short-term Investments $0·$9M$21M$0$0$42M$53M$35M$0··
Receivables $0$358.0K$0$6M$3M$2M$7M$3M$16M$57.0K$0$0
Prepaid Expense $1M$2M$198.0K$3M$7M$4M$4M$5M$2M$3M$2M$1M
Other Current Assets ···········$1M
Current Assets $59M$88M$8M$73M$128M$76M$115M$135M$90M$33M$32M$20M
PP&E (Net) ··$0$17M$19M$22M$20M$5M$4M$2M$2M$2M
PP&E (Gross) ···$27M$27M$28M$23M$8M$7M$5M$4M$4M
Accum. Depreciation ···$10M$8M$6M$4M$3M$3M$2M$2M$2M
Other Non-current Assets ··$0$1M$3M$3M$3M$910.0K$130.0K$126.0K$126.8K·
Total Assets $60M$88M$8M$95M$154M$105M$141M$141M$104M$35M$34M$22M
Accounts Payable $5M$5M$936.0K$4M$9M$2M$6M$3M$2M$2M$1M·
Accrued Liabilities ·····$8M$10M$9M$6M$4M$2M$986.6K
Current Liabilities $11M$12M$2M$37M$51M$22M$27M$48M$46M$8M$3M$4M
Capital Leases $431.0K$0$0$12M$14M$16M$15M$0····
Other Non-current Liabilities ···$0$0$6.0K$0$27.0K$37.0K$47.0K$23.9K$334.0K
Total Liabilities $32M$26M$11M$68M$103M$74M$90M$101M$92M$10M$3M$4M
Common Stock $12.0K$11.0K$0$74.0K$72.0K$56.0K$55.0K$54.0K$45.0K$43.0K$39.8K$29.3K
Paid-in Capital $163M$156M$2M$319M$307M·····$112M$85M
Retained Earnings $-135M$-94M$-76M$-290M$-257M$-211M$-174M$-147M$-120M$-103M$-80M$-66M
AOCI $83.0K$3.0K$0$-254.0K$829.0K$-295.0K$-2M$-3M$-5M$-2M$-1M$-843.1K
Stockholders' Equity $28M$63M$-74M$-94M$51M$31M$51M$40M$12M$25M$31M$18M
Liabilities + Equity $60M$88M$8M$95M$154M$105M$141M$141M$104M$35M$34M$22M
Shares Outstanding 12,380,93311,012,1051,770,16774,519,10372,222,66156,003,00055,212,43754,151,21945,017,06243,058,82739,833,02329,279,522
Cash Flow 13
Metric Trend 202520242023202220212020201920182017201620152014
D&A ··$2M$3M$2M·······
Stock-based Comp $6M$830.0K$603.0K$4M$5M$5M$5M$5M$3M$2M$1M$571.4K
Deferred Tax ··$0$0$0$0$0$-164.0K$0$0$0$0
Other Non-cash ···$-34M········
Operating Cash Flow $-25M$-11M$-14M$-60M$-8M$-46M$-52M$-1M$50M$-14M$-13M$-5M
CapEx ··$171.0K$1M$949.0K$3M$2M$2M$2M$560.0K$620.7K$267.4K
Investing Cash Flow ··$12M$-21M$-949.0K$39M$10M$-9M$-46M···
Stock Issued ··$20M$7M$38M$10M····$26M$12M
Net Stock Activity ···$7M········
Financing Cash Flow $-660.0K$87M$5M$7M$59M$10M$32M$49M$4M···
Net Change in Cash $-26M$76M$-9M$-79M$47M$8M$-13M$37M$9M$6.0K$11M$15M
Taxes Paid ···········$51.7K
Free Cash Flow ···$-61M·$-49M$-55M$-3M$48M···
Profitability 7
Metric Trend 202520242023202220212020201920182017201620152014
Operating Margin -1490.4%··-167.8%·-115.7%-58.7%-105.9%-57.7%···
Net Margin -1610.6%··-128.5%·-127.0%-55.0%-91.9%-69.8%···
Pretax Margin -1610.6%··-128.5%·-126.4%-55.0%-93.0%-65.5%···
EBITDA Margin -1490.4%··-157.1%·-115.7%-58.7%-105.9%-57.7%···
ROA -56.5%-36.4%·-26.7%·-30.3%-17.9%-21.8%-25.4%···
ROE -110.1%140.6%·-92.1%·-99.7%-70.8%-59.3%-96.0%···
ROIC -137.9%-22.5%·-155.7%·-109.8%-52.9%-76.3%-135.1%···
Liquidity & Solvency 2
Metric Trend 202520242023202220212020201920182017201620152014
Current Ratio 5.27.3·2.0·3.44.32.82.0···
Quick Ratio 5.17.0·1.8·3.34.12.71.9···
Efficiency 2
Metric Trend 202520242023202220212020201920182017201620152014
Asset Turnover 0.0··0.2·0.20.30.20.4···
Receivables Turnover 14.5··5.7·6.99.83.23.2···
Per Share 5
Metric Trend 202520242023202220212020201920182017201620152014
Book Value / Share $2.26$5.69·$0.37·$0.55$0.93$0.74$0.26···
Revenue / Share $0.23···········
Cash Flow / Share $-2.22$-4.87··········
Cash / Share $4.68$7.59·$0.52·$1.26$1.13$1.38$0.84···
EPS (TTM) $-3.71$-7.83$2.17$-0.70$-0.71$-0.68······
Growth Rates 2
Metric Trend 202520242023202220212020201920182017201620152014
Revenue YoY ··65.3%-17.6%7.1%·······
Revenue CAGR 3Y ··13.4%·········
Valuation (TTM) 10
Metric Trend 202520242023202220212020201920182017201620152014
Revenue TTM $20M$20M$43M$26M$31M$29M$46M$29M$25M$6M$3M$5M
Net Income TTM $-42M$-17M$19M$-33M$-46M$-37M$-25M$-27M$-18M$-23M$-14M$-10M
Market Cap $1.30B$132M·$6.20B·$11.20B$15.99B$11.52B$27.19B···
P/E -28.2-1.56.7-118.9-425.9-294.1······
P/S 66.26.8·239.4·382.0345.5396.01075.8···
P/B 46.32.1·222.0·361.0311.4288.62359.9···
P / Tangible Book 46.32.1··430.3361.0······
P / Cash Flow -51.8-12.2·-103.5·-244.0-304.8-10809.9546.5···
P / FCF ···-101.7·-230.4-291.1-4169.1568.8···
Earnings Yield -3.5%-65.2%14.9%-0.84%-0.23%-0.34%······

Most recent period on the left · null values shown as ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

16
Metric 2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenue · · $43M $26M $31M
Operating Margin % -1490.4% · · -167.8% ·
Net Income $-42M $-17M $19M $-33M $-46M
Diluted EPS $-3.71 $-7.83 $2.17 · $-0.71

Institutional owners (13F) 214 filers · $2.2B total · As of Sept. 30, 2026

17

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Holders 214
Value held $2.2B
New positions 35
Exited positions 19
Institutional activity — Q2 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
35 (-35 vs prior Q) 19 (-3 vs prior Q) 93 (+24 vs prior Q) 45 (+15 vs prior Q) +820K

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution Value Shares % of tracked 13F Type
MONTANOVA CAPITAL, LLC $173,512,745 1,135,406 7.97% Shares
JENNISON ASSOCIATES LLC $146,801,795 960,619 6.75% Shares
BlackRock, Inc. $140,343,317 918,357 6.45% Shares
Frazier Life Sciences Management, L.P. $134,848,368 882,400 6.20% Shares
First Light Asset Management, LLC $117,961,911 771,901 5.42% Shares
BVF INC/IL $102,815,615 672,789 4.72% Shares
STATE STREET CORP $99,817,745 653,172 4.59% Shares
VANGUARD CAPITAL MANAGEMENT LLC $78,517,999 513,794 3.61% Shares
FRONTIER CAPITAL MANAGEMENT CO LLC $73,175,272 478,833 3.36% Shares
FEDERATED HERMES, INC. $66,173,352 433,015 3.04% Shares
VANGUARD GROUP INC $58,679,676 560,616 2.70% Shares
Woodline Partners LP $48,522,948 317,517 2.23% Shares
ORBIMED ADVISORS LLC $44,678,455 292,360 2.05% Shares
GEODE CAPITAL MANAGEMENT, LLC $42,213,033 276,164 1.94% Shares
Siren, L.L.C. $39,348,858 257,485 1.81% Shares
PRIMECAP MANAGEMENT CO/CA/ $39,149,734 256,182 1.80% Shares
EVENTIDE ASSET MANAGEMENT, LLC $35,375,385 231,484 1.63% Shares
EMERALD ADVISERS, LLC $35,070,051 229,486 1.61% Shares
FMR LLC $32,831,927 214,841 1.51% Shares
ALLIANCEBERNSTEIN L.P. $31,557,391 253,168 1.45% Shares
MPM BIOIMPACT LLC $31,179,406 204,027 1.43% Shares
GOLDMAN SACHS GROUP INC $30,795,370 201,514 1.42% Shares
MORGAN STANLEY $27,725,827 181,428 1.27% Shares
First Turn Management, LLC $23,908,689 156,450 1.10% Shares
Bellevue Group AG $23,687,100 155,000 1.09% Shares
Caption Management, LLC $21,394,800 140,000 0.98% Put option
EMERALD MUTUAL FUND ADVISERS TRUST $19,843,219 129,847 0.91% Shares
VANGUARD PORTFOLIO MANAGEMENT LLC $19,707,973 128,962 0.91% Shares
SUSQUEHANNA INTERNATIONAL GROUP, LLP $18,430,092 120,600 0.85% Call option
Aberdeen Group plc $18,374,771 120,238 0.84% Shares
NORTHERN TRUST CORP $14,853,034 97,193 0.68% Shares
NEXTBio Capital Management LP $13,739,893 89,909 0.63% Shares
NEUBERGER BERMAN GROUP LLC $12,700,411 83,107 0.58% Shares
Clio Asset Management LLC $11,863,635 86,012 0.55% Shares
SUSQUEHANNA INTERNATIONAL GROUP, LLP $11,706,012 76,600 0.54% Put option
VANGUARD FIDUCIARY TRUST CO $11,307,916 73,995 0.52% Shares
UBS Group AG $11,083,424 72,526 0.51% Shares
Avidity Partners Management LP $10,697,400 70,000 0.49% Shares
AWM Investment Company, Inc. $10,608,153 69,416 0.49% Shares
SEVEN GRAND MANAGERS, LLC $9,169,200 60,000 0.42% Shares
Clearbridge Investments, LLC $9,068,458 59,341 0.42% Shares
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC $8,713,159 69,901 0.40% Shares
BANK OF AMERICA CORP /DE/ $8,336,942 54,554 0.38% Shares
RENAISSANCE TECHNOLOGIES LLC $8,140,721 53,270 0.37% Shares
MILLENNIUM MANAGEMENT LLC $7,979,038 52,212 0.37% Shares
Ensign Peak Advisors, Inc $7,894,681 51,660 0.36% Shares
HSBC HOLDINGS PLC $7,641,156 50,001 0.35% Shares
Nicholas Investment Partners, LP $7,597,905 49,718 0.35% Shares
Balyasny Asset Management L.P. $6,805,992 44,536 0.31% Shares
Lisanti Capital Growth, LLC $6,567,440 42,975 0.30% Shares

Show all 214 institutional owners →

Activists & 5%+ owners 3 positions

18

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer Filed Stake Status Purpose Filing
Kaupinen Wes, Wesley H. Kaupinen 2019 Irrevocable Trust dated February 28, 2019, Christine L. Kaupinen, Christine L. Kaupinen 2019 Irrevocable Trust dated February 28, 2019, Michael Christopher Dec. 20, 2024 14.60% Initial filing · SEC
Biotechnology Value Fund, L.P., BVF I GP LLC, Biotechnology Value Fund II, L.P., BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP Holdings LLC, BVF Partners L.P., BVF Inc., Mark N. Lampert ×2 filings Aug. 17, 2023 · Initial filing · SEC
OrbiMed Advisors LLC, OrbiMed Capital GP III LLC ×10 filings Sept. 27, 2018 · Initial filing · SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Company insiders 34 insiders · 16 officers · 19 directors

19
Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
Kaupinen Wes President and CEO Feb. 5, 2026 A · 0 0 $0
Stephen S. Yoder Chief Executive Officer Feb. 24, 2023 A 6,000 0 0 $0
Matthew E Korenberg CFO, Treasurer June 12, 2026 M 1,000 0 0 $0
Thomas Bures Chief Financial Officer Feb. 24, 2023 A · 0 0 $0
Allan Reine Chief Financial Officer Feb. 26, 2019 A 65,000 0 0 $0
Darlene M Deptula-Hicks SVP, Chief Financial Officer June 13, 2016 P 5,000 0 0 $0
Kathleen Goin Chief Operating Officer Oct. 21, 2026 M 0 0 36 $-6,043,773
Ashley Hartmann Kline Chief Commercial Officer Feb. 5, 2026 A · 0 0 $0
Jeffrey S Martini Chief Scientific Officer Feb. 5, 2026 A · 0 0 $0
PALVELLA THERAPEUTICS, INC. Chief Scientific Officer Feb. 5, 2025 A · 0 0 $0
Ahmed Mousa Chief Business Officer Feb. 24, 2023 A · 0 0 $0
Shane Olwill Chief Development Officer Feb. 24, 2023 A 4,638 0 0 $0
Hitto Kaufmann Chief Scientific Officer Feb. 24, 2023 A · 0 0 $0
Tim Demuth Chief Medical Officer May 13, 2022 P 6,000 0 0 $0
Louis Matis Chief Development Officer Feb. 26, 2019 A 10,000 0 0 $0
Claude Knopf Chief Business Officer Nov. 28, 2016 A · 0 0 $0
George M Jenkins Director Oct. 14, 2026 S 132,616 2 26 $-7,196,725
Christopher P Kiritsy Director Sept. 2, 2026 M 250 0 1 $-49,141
Matthew Pauls Director June 29, 2026 A · 0 0 $0
Tadd S. Wessel Director June 10, 2026 A · 0 0 $0
John Doux Director June 10, 2026 A · 0 0 $0
Todd C Davis Director June 10, 2026 A · 0 0 $0
Elaine J Heron Director June 10, 2026 A 47,812 1 0 $300,000
James A Geraghty Director Dec. 12, 2024 D 0 0 0 $0
Maya R. Said Director June 21, 2023 A · 0 0 $0
Ann Barbier Director June 21, 2023 A · 0 0 $0
Michael Richman Director June 21, 2023 A · 0 0 $0
Peter A Kiener Director June 21, 2023 A · 0 0 $0
Matthew L Sherman Director June 21, 2023 A · 0 0 $0
Jean-Pierre Bizzari Director Jan. 25, 2020 A · 0 0 $0
Steven Prelack Director Jan. 25, 2019 A · 0 0 $0
Julian Adams Director Jan. 25, 2018 A · 0 0 $0
Chau Quang Khuong Director Oct. 25, 2017 A 65,398 0 0 $0
Aquilo Capital Management, LLC 10% owner July 21, 2020 S 3,675,530 0 0 $0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

ETF ownership Held by 23 ETFs

20

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund Weight Units As of Source
PTH · Invesco Exchange-Traded Fund Trust 1.08% 24,553 SH Oct. 23, 2026 Daily
BBC · ETFis Series Trust I 0.86% 2,856 NS July 31, 2026 N-PORT
DWAS · Invesco Exchange-Traded Fund Trust … 0.73% 22,414 SH Oct. 23, 2026 Daily
LABU · Direxion Shares ETF Trust 0.39% 13,887 NS July 31, 2026 N-PORT
VFMO · VANGUARD WELLINGTON FUND 0.18% 22,955 SH Aug. 19, 2026 Daily
PWS · Pacer Funds Trust 0.11% 190 NS July 31, 2026 N-PORT
IWO · iShares Trust 0.11% 103,168 SH Sept. 11, 2026 Daily
VTWG · VANGUARD SCOTTSDALE FUNDS 0.10% 11,762 SH Aug. 19, 2026 Daily
IWM · iShares Trust 0.05% 280,820 SH Sept. 11, 2026 Daily
VTWO · VANGUARD SCOTTSDALE FUNDS 0.05% 63,184 SH Aug. 19, 2026 Daily
RSSL · Global X Funds 0.05% 5,240 NS July 31, 2026 N-PORT
ISCG · iShares Trust 0.02% 1,583 SH Sept. 11, 2026 Daily
FHLC · FIDELITY COVINGTON TRUST 0.02% 4,864 NS July 31, 2026 N-PORT
VXF · VANGUARD INDEX FUNDS 0.02% 113,556 SH Aug. 19, 2026 Daily
VHT · VANGUARD WORLD FUND 0.02% 30,157 SH Aug. 19, 2026 Daily
WSML · iShares Trust 0.02% 674 SH Sept. 10, 2026 Daily
IWV · iShares Trust 0.00% 3,420 SH Sept. 3, 2026 Daily
ITOT · iShares Trust 0.00% 14,740 SH Sept. 11, 2026 Daily
DFAC · Dimensional ETF Trust 0.00% 218 NS July 31, 2026 N-PORT
VTI · VANGUARD INDEX FUNDS 0.00% 388,390 SH Aug. 19, 2026 Daily
VTHR · VANGUARD SCOTTSDALE FUNDS 0.00% 904 SH Aug. 19, 2026 Daily
ISCB · iShares Trust · 450 SH Sept. 11, 2026 Daily
ISCV · iShares Trust · 1,075 SH Sept. 11, 2026 Daily

PVLA Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

21
rating · 22 analysts BUY
Median target $232.00 +85.5%
6 27.3% Strong Buy
15 68.2% Buy
1 4.5% Hold
0 0.0% Sell
0 0.0% Strong Sell

12-Month Price Target

15 analysts · 2026-10-26

Mean target $228.93 +83.0%

← Below all targets Current price $125.10
Low$205.00 Mean$228.93 High$267.00

Peer comparison (GICS sub-industry) Key metrics vs sector peers

22

FY basis, prices as of each company's last fiscal year-end close.

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
PVLA $1.30B -28.2 65.3% -1610.6% -110.1% ·
ADRX · · · · · ·
XNCR $1.10B -12.3 13.7% -73.2% -14.0% ·
SRPT $2.26B -3.0 15.6% -32.5% -57.1% ·
ZBIO $1.98B -4.3 100.0% -3777.4% -156.8% ·
MLYS $2.96B -15.8 · · -32.2% ·
VIR $841M -1.9 -7.6% -638.9% -51.1% ·
KLRA · · · · · ·
COAG · · · · · ·

Latest News Recent headlines mentioning this company

23
Palvella Stock Up 340% as Insider Sells Shares. Here's What the Move Does (And Does Not) Signal Nasdaq ·

My Metrics Your personal watchlist — selected rows from Full Fundamentals

26

Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Source: SEC 10-Q filed Aug 4, 2026